Mesa Laboratories, Inc. (MLAB)
| Market Cap | 714.82M +90.2% |
| Revenue (ttm) | 249.73M +3.0% |
| Net Income | 4.80M |
| EPS | 0.86 |
| Shares Out | 5.60M |
| PE Ratio | 148.39 |
| Forward PE | 57.67 |
| Dividend | $0.64 (0.50%) |
| Ex-Dividend Date | Nov 30, 2026 |
| Volume | 100,247 |
| Open | 125.18 |
| Previous Close | 126.16 |
| Day's Range | 125.00 - 129.06 |
| 52-Week Range | 69.43 - 144.35 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 117.50 (-8.02%) |
| Earnings Date | Nov 9, 2026 |
About MLAB
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MLAB stock is "Buy." The 12-month stock price target is $117.5, which is a decrease of -8.02% from the latest price.
News
Mesa Labs to reduce workforce by 6% in global restructuring program
Mesa Labs (MLAB) announced a savings plan expected to reduce annualized operating costs by approximately $9.3M. The plan consists of a global restructuring program, a reduction in its San Diego,…
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solut...
Mesa Labs price target raised to $110 from $94 at Wells Fargo
Wells Fargo analyst Brandon Couillard raised the firm’s price target on Mesa Labs (MLAB) to $110 from $94 and keeps an Equal Weight rating on the shares. The firm notes…
Mesa Laboratories Earnings Call Transcript: Q1 2027
Revenue grew 1% year-over-year to $60.1 million, with strong margin expansion and adjusted operating income up 16.5%. SDC faced delivery reliability issues, but trailing 12-month revenue rose 5%. Focus remains on execution, deleveraging, and reinvestment in high-return segments.
Mesa Laboratories Earnings release: Q1 2027
Mesa Laboratories released its Q1 2027 earnings on August 10, 2026, summarizing the period's financial results.
Mesa Laboratories Quarterly report: Q1 2027
Mesa Laboratories has published its Q1 2027 quarterly earnings report on August 10, 2026.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and...
Mesa Laboratories Proxy statement: Proxy filing
Mesa Laboratories filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.
MESA LABS DECLARES QUARTERLY DIVIDEND
Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quart...
Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical qual...
Mesa Laboratories Earnings release: Q4 2026
Mesa Laboratories released its Q4 2026 earnings on May 27, 2026, summarizing the period's financial results.
Mesa Laboratories Slides: Q4 2026
Mesa Laboratories has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 27, 2026.
Mesa Laboratories Annual report: Q4 2026
Mesa Laboratories has published its Q4 2026 annual report on May 27, 2026.
Mesa Laboratories Annual report: Q4 2026
Mesa Laboratories has published its Q4 2026 annual report on May 27, 2026.
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 202...
Mesa Labs CEO Gary Owens to step down, Siddhartha Kadia to succeed
Mesa Labs (MLAB) announced that Gary Owens will step down as president and CEO on April 12 and will enable a leadership transition. To lead the company’s next chapter, the…
Mesa Labs price target raised to $94 from $83 at Wells Fargo
Wells Fargo raised the firm’s price target on Mesa Labs (MLAB) to $94 from $83 and keeps an Equal Weight rating on the shares. The firm notes the company posted…
Mesa Laboratories Quarterly report: Q3 2026
Mesa Laboratories has published its Q3 2026 quarterly earnings report on February 3, 2026.
Mesa Laboratories Earnings release: Q3 2026
Mesa Laboratories released its Q3 2026 earnings on February 3, 2026, summarizing the period's financial results.
Mesa Laboratories Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company highlighted its strong recurring revenue base, disciplined growth through both organic initiatives and strategic acquisitions, and resilience amid recent market headwinds. With a focus on regulated markets and continuous operational improvement, it expects accelerating growth as clinical trial activity rebounds.
Mesa Laboratories Slides: 44th Annual J.P. Morgan Healthcare Conference
Mesa Laboratories has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, to...
Mesa Labs price target raised to $83 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on Mesa Labs (MLAB) to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on…
Mesa Laboratories Transcript: Jefferies London Healthcare Conference 2025
Biopharmaceutical development and calibration solutions showed strong growth, with regional disparities in clinical genomics due to China headwinds. Cost reductions and reinvestments are supporting commercialization and operational improvements, while M&A and APAC expansion remain strategic priorities.
Mesa Laboratories, Inc. to Participate in Upcoming Investor Conferences
LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcomin...